Objective:

To evaluate the impact of early initiation of sacubitril/valsartan on myocardial recovery and clinical outcomes in elderly patients with left ventricular dysfunction after PCI.

Key Findings:

• Early initiation group showed the greatest improvement in left ventricular ejection fraction and cardiac index at 8 weeks.
• Early initiation was associated with larger reductions in left ventricular dimensions and favorable declines in inflammatory and cardiac injury biomarkers.
• MACE occurred in 8.3% of the early group, 20.8% of the delayed group, and 25.0% of the control group.
• Early initiation was linked to a significantly lower risk of MACE compared to delayed initiation and no sacubitril/valsartan.
• Stronger associations were observed in patients aged ≥75 years and those with baseline LVEF ≤40%.

Interpretation:

Remove this section.

Limitations:

• Residual confounding and potential immortal time bias cannot be excluded.
• Findings are hypothesis-generating and not confirmatory.

Conclusion:

Rephrase to avoid suggesting potential associations and focus on the findings.